FDA Approves Illumina’s TruSight Oncology Comprehensive Test for Pan-Cancer Companion Diagnostics

FDA approval, Illumina, TruSight Oncology Comprehensive, pan-cancer, companion diagnostics, NTRK gene fusions, RET fusion-positive NSCLC, targeted therapies, precision oncology.

Can Element Biosciences Challenge Illumina in the DNA Sequencing Market?

Element Biosciences, Illumina, DNA sequencing, next-generation sequencing (NGS), Avidity Base Chemistry (ABC), sequencing by synthesis (SBS), Cloudbreak, Aviti sequencer, genomics, biotechnology, market competition